SOF/VEL/VOX for 12 weeks in NS5A-inhibitor experienced HCV-infected patients: Results of the deferred treatment group in the phase 3 POLARIS-1 study.

Authors

M BourlièreFollow
Stuart C. Gordon, Henry Ford HealthFollow
E R. Schiff
T T. Tran
N Ravendhran
C S. Landis
R H. Hyland
J Zhang
H Dvory-Sobol
Luisa M. Stamm
D M. Brainard
J G. McHutchison
L Serfaty
A J. Thompson
T E. Sepe
M P. Curry
K R. Reddy
M P. Manns

Recommended Citation

Bourliere M, Gordon SC, Schiff ER, Tran TT, Ravendhran N, Landis CS, Hyland RH, Zhang J, Dvory-Sobol H, Stamm LM, Brainard DM, McHutchison JG, Serfaty L, Thompson AJ, Sepe TE, Curry MP, Reddy KR, and Manns MP. SOF/VEL/VOX for 12 weeks in NS5A-inhibitor experienced HCV-infected patients: Results of the deferred treatment group in the phase 3 POLARIS-1 study. Hepatology 2017; 66:633A-634A.

Document Type

Conference Proceeding

Publication Date

2017

Publication Title

Hepatol

Volume

66

First Page

633A

Last Page

634A